FIELD: organic chemistry.
SUBSTANCE: invention relates to crystalline form C of hydrochloride salt of [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (Compound I), which is characterized by an X-ray powder diffraction pattern comprising peaks (±0.2°) at 7.3, 16.6, 20.9, 23.3 and 28.2 °2θ, determined on a diffractometer using Cu-Kα radiation. Invention also relates to a method of treating or preventing and to use for treating or preventing a disease mediated by protein kinase, selected from c-fms, c-kit, Flt3 or a combination thereof.
EFFECT: obtaining a crystalline form of the compound of formula I, having useful biological properties.
25 cl, 23 dwg, 11 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION | 2016 |
|
RU2744897C2 |
| POLYMORPHOUS FORMS OF ICOTINIB MALEATE AND USES THEREOF | 2014 |
|
RU2708079C2 |
| POLYMORPHIC FORMS OF ICOTINIB AND USES THEREOF | 2014 |
|
RU2710013C2 |
| CRYSTALLINE DIACILHYDRAZINE AND ITS APPLICATION | 2012 |
|
RU2629113C2 |
| POLYMORPHS OF KINASE INHIBITOR | 2012 |
|
RU2636588C2 |
| LIQUID COMPOSITIONS (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-YL)-3-HYDROXYPYRROLIDINE-1-ARBOXAMIDE | 2017 |
|
RU2751767C2 |
| METHOD OF PRODUCING CRYSTALLINE FORM OF MNK INHIBITORS | 2019 |
|
RU2821258C2 |
| METHODS FOR TREATMENT OF CHILDHOOD CANCER DISEASES | 2017 |
|
RU2751636C2 |
| PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
| 3-[1,2,3,6-TETRAHYDROPYRIDIN-2-YL]PYRIDINE GLUTARATE OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | 2019 |
|
RU2823979C2 |
